Clenbuterol is a long-acting, selective β₂ adrenergic receptor agonist. β₂AR activation triggers adenylyl cyclase → elevated cAMP → protein kinase A (PKA) activation. In bronchial smooth muscle: bronchodilation. In adipose tissue: upregulates hormone-sensitive lipase (HSL) and cAMP-mediated lipolysis. In skeletal muscle: anabolic signalling via cAMP/PKA — protein synthesis, anti-atrophy effects. The long half-life (~36h) allows once-daily dosing designs in research. FDA-approved in USA for veterinary bronchospasm (horses). Extensively studied for the combination of lipolytic and muscle-sparing/anabolic effects in body composition research models.
Also Known As
Spiropent, Ventipulmin, Clen, NAB 365
Compound Class
Beta-2 adrenergic receptor (β₂AR) agonist
Molecular Formula
C₁₂H₁₈Cl₂N₂O
Molecular Weight
277.19 Da
CAS Number
37148-27-9
Half-Life
~35–39 hours
Research Applications
Lipolysis / Fat Loss Research
β₂AR activation in adipocytes: PKA phosphorylates HSL → triglyceride hydrolysis, increased FFA release. DIO rodent models: clenbuterol reduces fat mass with dose-dependent effect. Compared vs thyroid hormone and PPAR agonists in metabolic research designs.
Skeletal Muscle Anabolism / Anti-Atrophy
Clenbuterol has well-characterised anti-catabolic and anabolic effects in skeletal muscle — increases muscle fibre cross-sectional area, reduces protein degradation via UPS. Studied in denervation atrophy, disuse atrophy, and cancer cachexia rodent models.
Bronchodilation / Respiratory Research
Long-acting β₂AR agonist — reference compound for airway smooth muscle relaxation research. Compared vs salbutamol (short-acting) and salmeterol in bronchospasm and COPD models. Dose-response in tracheal ring preparations.
Cardiac β₂AR Research
At higher doses, clenbuterol engages cardiac β₂AR — positive chronotropic and inotropic effects. Studied in heart failure models for β₂AR-mediated cardioprotection. Tachycardia is primary adverse signal in dose-escalation research.
Key Research Data
Study
Key Findings
Emery et al. 1984 Br J Pharmacol
β₂ selectivity profile: clenbuterol vs isoprenaline — β₂/β₁ ratio characterised, bronchial vs cardiac effects
Adipocyte clenbuterol: HSL activation, lipolysis dose-response, β₂AR density in rat adipose
Specifications
Format
Oral tablet — 40mcg per tablet
Purity
≥99% HPLC
Identity
MS confirmed
Storage
Room temperature
Half-life
~36 hours — long-acting vs salbutamol (~4h) for once-daily research designs
FAQ
What is Clenbuterol (Spiropent)?
Clenbuterol (Spiropent) is a Beta-2 adrenergic receptor (β₂AR) agonist. Clenbuterol is a long-acting, selective β₂ adrenergic receptor agonist. β₂AR activation triggers adenylyl cyclase → elevated cAMP → protein kinase A (PKA) activation. In bronchial smooth muscle: bronchodilation. In adipose tissue: upregulates hormone-sensitive…
What research applications does Clenbuterol support?
β₂AR activation in adipocytes: PKA phosphorylates HSL → triglyceride hydrolysis, increased FFA release. DIO rodent models: clenbuterol reduces fat mass with dose-dependent effect. Compared vs thyroid hormone and PPAR agonists in metabolic research designs….
How does Clenbuterol compare to similar compounds?
Clenbuterol has well-characterised anti-catabolic and anabolic effects in skeletal muscle — increases muscle fibre cross-sectional area, reduces protein degradation via UPS. Studied in denervation atrophy, disuse atrophy, and cancer cachexia rodent models….
Does QSC ship Clenbuterol to the USA?
Yes. QSC ships domestically across the USA and to EU, UK, Canada, and Australia. Every batch carries a Janoshik third-party COA confirming ≥99% HPLC purity and MS identity.
